Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
10/15/20	G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)
9/30/20	G1 Therapeutics Announces Chief Executive Officer Succession Plan
9/14/20	G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress
9/2/20	G1 Therapeutics to Participate in Four Investor Conferences in September 2020
8/17/20	G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
8/5/20	G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
8/4/20	G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020
8/3/20	G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
7/29/20	G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
7/22/20	G1 Therapeutics Announces License Agreement for Lerociclib